Cancer Institute

Tampa General Hospital Brings New Hope for Patients with Advanced Blood Cancers

Retrieved on: 
Monday, March 4, 2024

TAMPA, Fla., March 4, 2024 /PRNewswire/ -- As part of its commitment to harness innovative advances in cancer care, the Tampa General Hospital (TGH) Cancer Institute has added a novel approach to its therapeutic armamentarium for the treatment of patients with aggressive forms of B-cell non-Hodgkin lymphomas and other types of blood cancers.

Key Points: 
  • The field of immunotherapy has evolved from an academic research program to an essential pillar in the treatment of many cancers.
  • All are intended for the treatment of blood cancers, including lymphomas, some forms of leukemia and, most recently, multiple myeloma.
  • Following comprehensive planning and discussion, Tampa General's Hospital at Home program has started to be applied to CAR T patients meeting certain criteria.
  • Due the benefit of remote monitoring, the TGH Cancer Institute and Hospital at Home teams have been working on adapting Hospital at Home for oncology patients.

Varian Receives FDA 510(k) Clearance for TrueBeam and Edge Radiotherapy Systems Featuring HyperSight Imaging Solution

Retrieved on: 
Thursday, February 29, 2024

HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues

Key Points: 
  • HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues
    PALO ALTO, Calif., Feb. 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution.
  • By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators.
  • HyperSight on TrueBeam and Edge acquires images for all anatomical sites with a 50% faster gantry rotation, significantly reducing acquisition time.
  • VARIAN, TRUEBEAM, EDGE, ETHOS, HALCYON, HYPERSIGHT are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

New Chair and Executive Committee Members Appointed of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – is pleased to announce Tycel Phillips, MD of City of Hope and Kami Maddocks, MD of Ohio State University to the Executive Committee members and Peter Martin, MD of Weill Cornell Medicine as Chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • "LRF's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, CEO of the Lymphoma Research Foundation
    The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception the Mantle Cell Lymphoma Consortium brings together leading international experts to discuss the latest research findings, foster collaboration within the mantel cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
  • "I'm honored to lead this vital consortium dedicated to improving outcomes for all those impacted by mantle cell lymphoma," said Dr. Martin.

In the War on Cancer, Tampa General Hospital Cancer Institute Employs AI in its Newly Established Center for Precision Radiosurgery

Retrieved on: 
Thursday, January 25, 2024

TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute, where doctors are using a sophisticated AI-driven tool to treat cancer.

Key Points: 
  • TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute , where doctors are using a sophisticated AI-driven tool to treat cancer.
  • It is capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders, in as little as 15 minutes.
  • The tool, through its speed and advanced precision, is expected to expand the capabilities of Tampa General Cancer Institute's newly established Center for Precision Radiosurgery, said Dr. Richard Tuli, professor and chair of the Department of Radiation Oncology at USF Health Morsani College of Medicine, deputy director of the TGH Cancer Institute, and director of Radiation Oncology at Tampa General.
  • Tuli joined TGH from Memorial Sloan Kettering Cancer Center in New York, N.Y.
    "It's another example of providing our patients with the best possible care across the Tampa Bay region and the state,'' he said.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Retrieved on: 
Sunday, December 10, 2023

Finally, in an oral presentation pre-clinical and Phase I clinical data from AUTO8, a BCMA/CD19 co-targeting CAR T cell candidate, evaluated in patients with refractory multiple myeloma.

Key Points: 
  • Finally, in an oral presentation pre-clinical and Phase I clinical data from AUTO8, a BCMA/CD19 co-targeting CAR T cell candidate, evaluated in patients with refractory multiple myeloma.
  • “The FELIX study, with 127 patients, is one of the largest CAR T cell studies in adults with r/r B-ALL.
  • A high proportion of patients responded, with many responses sustained, particularly in patients with low or intermediate disease-burden at lymphodepletion.
  • Cellular kinetic data shows high expansion and long-term persistence of CAR T cells in most responders.

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Retrieved on: 
Wednesday, November 15, 2023

Time: The presentation will be from 8:00 AM PT / 4:00 PM GMT to 9:00 AM PT / 5:00 PM GMT.

Key Points: 
  • Time: The presentation will be from 8:00 AM PT / 4:00 PM GMT to 9:00 AM PT / 5:00 PM GMT.
  • Onsite access to the event available from 7:45am PT
    Speakers: Dr. Claire Roddie, MD, PhD, FRCPath, Associate Professor Haematology and Honorary Consultant Haematologist, Cancer Institute, University College London (UCL); Dr. Christian Itin, Chief Executive Officer, Autolus.
  • Webcast Registration: A live webcast will be held alongside the event.
  • A recording of the event together with the presentation materials will be available on the Company’s website after the event.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

Tampa General and Synapse Florida Seek Innovation Solutions to Reduce Cancer Mortality in Rural Communities

Retrieved on: 
Tuesday, November 28, 2023

TAMPA, Fla., Nov. 28, 2023 /PRNewswire/ -- Cancer care, whether for yourself or a loved one, can be one of the most difficult challenges in anyone's life, especially for those with limited access to early detection, care and treatment. Tampa General Hospital (TGH) and its Cancer Institute partnered with Synapse Florida to issue a challenge and invite innovative solutions that can provide potentially lifesaving care and reduce cancer mortality in rural areas.

Key Points: 
  • Tampa General Hospital (TGH) and its Cancer Institute partnered with Synapse Florida to issue a challenge and invite innovative solutions that can provide potentially lifesaving care and reduce cancer mortality in rural areas.
  • "Through TGH Innoventures and in partnership with Synapse, we're working to incentivize innovation so that we can transform care delivery.
  • The Innovation Challenge encourages individuals and organizations to propose innovative solutions that address the significant need for cancer care where it otherwise may not exist.
  • This initiative enables Tampa General to crowdsource ideas from a broad cross section of the innovation ecosystem both locally in Florida, as well as nationally and globally.

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

Retrieved on: 
Thursday, November 2, 2023

Additionally, we will be presenting the first AUTO8 clinical data from the MCARTY Phase I study in multiple myeloma.”

Key Points: 
  • Additionally, we will be presenting the first AUTO8 clinical data from the MCARTY Phase I study in multiple myeloma.”
    Session Title: 704.
  • In this session, pooled analysis of data from all patients treated to date in the FELIX study will be presented, with an extended follow up.
  • In the MCARTY study, we demonstrate dual CD19/BCMA targeting, alongside feasibility of clinical grade manufacture by double-transduction.
  • Additionally, obe-cel has been tested in patients with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL).

Mevion Selected to Equip BayCare’s Proton Therapy Center in Tampa

Retrieved on: 
Friday, November 3, 2023

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.
  • “BayCare is bringing an advanced proton radiation therapy center to Tampa so patients in our community don’t have to drive to Orlando or beyond to get this level of high-quality care.”
    The MEVION S250-FIT Proton Therapy System is thoughtfully designed to expedite proton therapy project timelines with a compact footprint, reduced construction requirements, and accelerated installation process.
  • “We are dedicated to advancing proton therapy technology and access, and I look forward to making a meaningful difference to patients and families across West Central Florida.”
    *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy.